Economic considerations in overactive bladder
- PMID: 11183902
Economic considerations in overactive bladder
Abstract
Many costs are associated with overactive bladder (OAB). They include direct costs, such as those associated with treatment, diagnosis, routine care, and the consequences of the disease; indirect costs of lost wages and productivity; and intangible costs associated with pain, suffering, and decreased quality of life. Quantification of all these costs is essential for establishing the total economic burden of a disease on society. Currently, the total economic burden of OAB is unknown. However, various studies have determined that the economic burden of urinary incontinence, one of the symptoms of OAB, is substantial. It is also important to establish the economic impact of various interventions for OAB. Cost-minimization, cost-outcome, cost-utility, and cost-benefit models can be used for these analyses. The most difficult aspect of evaluating the economic impact of a treatment is estimating the intangible costs.
Similar articles
-
The economic impact of overactive bladder syndrome in six Western countries.BJU Int. 2009 Jan;103(2):202-9. doi: 10.1111/j.1464-410X.2008.08036.x. BJU Int. 2009. PMID: 19278532
-
Health-related consequences of overactive bladder: an economic perspective.BJU Int. 2005 Sep;96 Suppl 1:43-5. doi: 10.1111/j.1464-410X.2005.05654.x. BJU Int. 2005. PMID: 16086679
-
The current and future burden and cost of overactive bladder in five European countries.Eur Urol. 2006 Nov;50(5):1050-7. doi: 10.1016/j.eururo.2006.04.018. Epub 2006 May 9. Eur Urol. 2006. PMID: 16753252
-
Defining overactive bladder: epidemiology and burden of disease.Urology. 2004 Dec;64(6 Suppl 1):2-6. doi: 10.1016/j.urology.2004.10.047. Urology. 2004. PMID: 15621220 Review.
-
Lower urinary tract symptoms in women.Curr Opin Urol. 2009 Jul;19(4):337-41. doi: 10.1097/MOU.0b013e32832b659d. Curr Opin Urol. 2009. PMID: 19444118 Review.
Cited by
-
Oxybutynin topical gel in the treatment of overactive bladder.Open Access J Urol. 2010 Jun 16;2:91-8. Open Access J Urol. 2010. PMID: 24198618 Free PMC article. Review.
-
Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.Curr Med Res Opin. 2021 Aug;37(8):1303-1313. doi: 10.1080/03007995.2021.1920899. Epub 2021 May 13. Curr Med Res Opin. 2021. PMID: 33890538 Free PMC article.
-
Urodynamic Effects of Propiverine on Detrusor Overactivity and Abdominal Straining during Voiding in Awake Rats with Intravesical Prostaglandin E(2) Instillation.Korean J Urol. 2010 Jan;51(1):64-9. doi: 10.4111/kju.2010.51.1.64. Epub 2010 Jan 21. Korean J Urol. 2010. PMID: 20414414 Free PMC article.
-
Emerging treatments for overactive bladder: clinical potential of botulinum toxins.Res Rep Urol. 2014 May 21;6:51-7. doi: 10.2147/RRU.S44665. eCollection 2014. Res Rep Urol. 2014. PMID: 24892033 Free PMC article. Review.
-
Clinical impact of overactive bladder.Rev Urol. 2002;4 Suppl 4(Suppl 4):S2-6. Rev Urol. 2002. PMID: 16986018 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources